Platinum-based chemotherapy for advanced non-small-cell lung cancer

Anne M. Traynor, Joan H. Schiller

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Summary: Platinum compounds provide the foundation for the treatment of patients with advanced NSCLC. Treatments with such regimens offer patients with an improvement in good performance status, in quality of life and prolonged survival, compared to BSC. Carboplatin very likely offers similar efficacy outcomes compared to cisplatin in this setting, and with less toxicity. Treatment with a platinum-based doublet incorporating a newer, third-generation cytotoxic agent is the recommended therapy for good-performance-status patients with advanced NSCLC, yielding an approximate response rate of 30%, median survival of 8-12 months, 1-year survival of 30%, and 2-year survival of 10%. No single regimen is recommended as superior; selection of the regimen can be flexible, contingent upon the patient's comorbidities, treatment cost, and administration schedule. Adding a third cytotoxic agent is only likely to exacerbate toxicity, without improving efficacy. Treatment should be limited to four cycles in patients with stable disease, and possibly a maximum of six cycles, as tolerated, in responding patients. Age alone should not preclude consideration for treatment with a platinum doublet, although prospective data using platinum agents in studies restricted to elderly patients are lacking. Finally, research continues into the identification of platinum-sensitive patients based upon pharmacoge-nomic parameters, and the development of newer platinum compounds.

Original languageEnglish (US)
Title of host publicationTumors of the Chest
Subtitle of host publicationBiology, Diagnosis and Management
PublisherSpringer Berlin Heidelberg
Pages273-288
Number of pages16
ISBN (Print)6293603618, 9783540310396
DOIs
StatePublished - Dec 1 2006

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Platinum-based chemotherapy for advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this